← All trials
NCT06304623
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 5, 2020
- Primary completion
- Mar 1, 2024
- Completion date
- Mar 1, 2024
- First posted
- Mar 12, 2024
- Last posted
- Mar 12, 2024
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Wake Forest UniversityLead sponsor
- Wake Forest UniversityCollaborator
- government of nicaraguaCollaborator
- National Autonomous University of NicaraguaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.